1. 迷迭香提取物rosemary leaf extract

迷迭香提取物

品名: 迷迭香提取物

拉丁名: Rosmarinus officinalis

颜色: 浅黄色至黄绿色精细粉末

 

规格: 鼠尾草酸：1%-95%，油溶

          熊果酸：5%-98%，HPLC，油溶

          迷迭香酸：2.5%-98%，水溶

          迷迭香精油：100%

           比例: 5:1,10:1,20:1 TLC.

 检测方式: HPLC / TCL

 

迷迭香(Rosmarinus oficinalis L.)也叫油安草，系唇形科鼠尾草属植物,常绿小灌木，原产欧洲、北非及地中海沿岸,近年来在我国云南、广西、海南、湖南、四川、贵州、福建等省区均有种植。迷迭香是一种多用途的经济作物,从中可提取抗氧化剂、迷迭香精油等。抗氧化剂的主要成分是具有抗氧化功能的二萜类、黄酮类、三萜类等化合物;迷迭香精油则是一种由30多种挥发性成分组成的液态油状物。
迷迭香提取物具有高效、安全等特性,广泛应用于化妆品、香水、香皂、空气清新剂驱虫剂、医药各种动植物油脂、动物饲料、肉制品、海产品、面粉、调味酱、调味料、烘焙食品、油炸产品、天然色素、香精、生物农药、烟草等领域，特别是可以治疗血液恶性肿瘤、心血管病、 、抑制艾滋病毒的感染、治疗消化不良、预防老年痴呆症、心脏病、高尿酸血症以及呼吸系统的疾病等,为生产、生活带来了许多方便。在欧洲,迷迭香作为食品香料有悠久的历史,现已应用于化妆品、食品以及药品等方面。现有研究表明,迷迭香在防止油脂氧化、保持肉类风味等方面具有明显效果,日本现已开发出系列迷迭香抗氧化剂产品。

迷迭香提取物的功效

1.天然抗氧化剂，广泛应用于食品、功能性食品、调味品、调味品、日用化工等行业；

 2.抗衰老作用。它能清除体内过量产生的自由基，消灭单线态氧，保护细胞膜结构，延缓衰老过程；

 3.减肥效果强。它可以通过抗氧化剂的作用刺激和加速脂肪的代谢。它不仅能降低血压，还能促进粪便中的脂类化合物排出，从而达到减肥的目的；

 4.具有 作用，可用于治疗心血管疾病。

 

 

迷迭香提取物的应用

1.作为天然抗氧化剂，其抗氧化活性高于VE。广泛应用于化妆品、食品、香料、香水、沐浴露、洗发水、香皂、空气清新剂等。

 2.迷迭香提取物作为一个 的神经和大脑补充剂，提高记忆技能和注意力。迷迭香油浓烈的花香使人放松，对神经系统有刺激作用。它刺激大脑和中枢神经系统，对抗精神疲劳，从而提高精神清晰度。它是治疗抑郁、无聊、疲劳和健忘的良药。

 3.它能保护脑细胞免受衰老过程的影响，增强记忆力。

 4.众所周知，迷迭香提取物能保护皮肤细胞，防止皱纹和黑斑形成等与年龄有关的皮肤变化，保护皮肤细胞免受老化造成的损害，从而延缓皱纹和皮肤下垂的发生。

References参考文献:

  1. 1. 

    Vidak M, Rozman D, Komel R. Effects of flavonoids from food and dietary supplements on glial and Glioblastoma Multiforme cells. Mol Ther. 2015 Oct 23;20(10):19406–32.

  2. 2. 

    Li Y, Go VL, Sarkar FH. The role of Nutraceuticals in pancreatic cancer prevention and therapy: targeting cellular signaling, MicroRNAs, and Epigenome. Pancreas. 2015 Jan;44(1):1–10.

  3. 3. 

    Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Anticancer Efficacy of Polyphenols and Their Combinations. Nutrients. 2016 Sep 9;8(9). pii: E552.

  4. 4. 

    Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep. 2000 Jun;17(3):215–34.

  5. 5. 

    Gilbert B, Alves LF. Synergy in plant medicines. Curr Med Chem. 2003 Jan;10(1):13–20.

  6. 6. 

    González-Vallinas M, González-Castejón M, Rodríguez-Casado A, Ramírez de Molina A. Dietary phytochemicals in cancer prevention and therapy: a complementary approach with promising perspectives. Nutr Rev. 2013;71:585–99.

  7. 7. 

    Helmerick EC, Loftus JP, Wakshlag JJ. The effects of baicalein on canine osteosarcoma cell proliferation and death. Vet Comp Oncol. 2014;12:299–309.

  8. 8. 

    Wakshlag JJ, Balkman CE. Effects of lycopene on proliferation and death of canine osteosarcoma cells. Am J Vet Res. 2010;71:1362–70.

  9. 9. 

    Wakshlag JJ, Balkman CA, Morgan SK, McEntee MC. Evaluation of the protective effects of all-trans-astaxanthin on canine osteosarcoma cell lines. Am J Vet Res. 2010;71:89–96.

  10. 10. 

    Kelsey JL, Moore AS, Glickman LT. Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol Rev. 1998;20:2014–7.

  11. 11. 

    Levine CB, Bayle J, Biourge V, Wakshlag JJ. Effects and synergy of feed ingredients on canine neoplastic cell proliferation. BMC Vet Res. 2016 Aug 2;12(1):159.

  12. 12. 

    Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7:1894–900.

  13. 13. 

    Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 2014 Aug;11(8):1183–201.

  14. 14. 

    Douglass BJ, Clouatre DL. Beyond yellow curry: assessing commercial Curcumin absorption technologies. J Am Coll Nutr. 2015;34(4):347–58.

  15. 15. 

    Berginc K, Trontelj J, Basnet NS, Kristl A. Physiological barriers to the oral delivery of curcumin. Pharmazie. 2012 Jun;67(6):518–24.

  16. 16. 

    Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009 Jun 28;37(3–4):223–30.

  17. 17. 

    Pesakhov S, Khanin M, Studzinski GP, Danilenko M. Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. Nutr Cancer. 2010;62:811–24.

  18. 18. 

    Einbond LS, HA W, Kashiwazaki R, He K, Roller M, Su T, et al. Carnosic acid inhibits the growth of ER-negative human breast cancer cells and synergizes with curcumin. Fitoterapia. 2012;83:1160–8.

  19. 19. 

    Passos JF, Miwa S, von Zglinicki T. Measuring reactive oxygen species in senescent cells. Methods Mol Biol. 2013;965:253–63.

  20. 20. 

    Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta. 2008 Apr;1780(4):673–9.

  21. 21. 

    Rasband, WS. ImageJ. U.S. National Institutes of Health, Bethesda, Maryland, USA. 1997-2016.

  22. 22. 

    Wakshlag JJ, Kallfelz FA, Wakshlag RR, Davenport GM. The effects of branched-chain amino acids on canine neoplastic cell proliferation and death. J Nutr. 2006 July;136(7 Suppl):2007S–10S.

  23. 23. 

    Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem. 2007 Jul;18(7):427–42.

  24. 24. 

    Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009 Sep;11(3):495–510.

  25. 25. 

    Plouzek CA, Ciolino HP, Clarke R, Yeh GC. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer. 1999 Oct;35(10):1541–5.

  26. 26. 

    Chen J, Li L, Su J, Li B, Zhang X, Chen T. Proteomic analysis of G2/M arrest triggered by natural Borneol/Curcumin in HepG2 cells, the importance of the reactive oxygen species-p53 pathway. J Agric Food Chem. 2015 Jul 22;63(28):6440–9.

  27. 27. 

    Lim TG, Lee SY, Huang Z, Lim DY, Chen H, Jung SK, et al. Curcumin suppresses proliferation of colon cancer cells by targeting CDK2. Cancer Prev Res (Phila). 2014 Apr;7(4):466–74.

  28. 28. 

    Baharuddin P, Satar N, Fakiruddin KS, Zakaria N, Lim MN, Yusoff NM, et al. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol Rep. 2016 Jan;35(1):13–25.

  29. 29. 

    Kumar D, Basu S, Parija L, Rout D, Manna S, Dandapat J, Debata PR. Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. Biomed Pharmacother. 2016 July;81:31–7.

  30. 30. 

    Mosieniak G, Sliwinska MA, Przybylska D, Grabowska W, Sunderland P, Bielak-Zmijewska A, Sikora E. Curcumin-treated cancer cells show mitotic disturbances leading to growth arrest and induction of senescence phenotype. Int J Biochem Cell Biol. 2016 May;74:33–43.

  31. 31. 

    Tong L, Chuang CC, Wu S, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Lett. 2015 Oct 10;367(1):18–25.

  32. 32. 

    Deng Y, Verron E, Rohanizadeh R. Molecular mechanisms of anti-metastatic activity of Curcumin. Anticancer Res. 2016 Nov;36(11):5639–47.

  33. 33. 

    Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors. 2013 Jan-Feb;39(1):27–36. 

  34. 34. 

    Khuda-Bukhsh AR, Das S, Saha SK. Molecular approaches toward targeted cancer prevention with some food plants and their products: inflammatory and other signal pathways. Nutr Cancer. 2014;66(2):194–205. 

  35. 35. 

    Moore J, Yousef M, Tsiani E. Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols. Nutrients. 2016 Nov 17;8(11). pii: E731.

  36. 36. 

    Tai J, Cheung S, Wu M, Hasman D. Antiproliferation effect of rosemary (Rosmarinus Officinalis) on human ovarian cancer cells in vitro. Phytomedicine. 2012;19:436–43.

  37. 37. 

    Tsai CW, Lin CY, Lin HH, Chen JH. Carnosic acid, a rosemary phenolic compound, induces apoptosis through reactive oxygen species-mediated p38 activation in human neuroblastoma IMR-32 cells. Neurochem Res. 2011;36:2442–51.

  38. 38. 

    Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, et al. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer. 2011 Mar 28;11:112.

  39. 39. 

    Verheij M, Ruiter GA, Zerp SF, van Blitterswijk WJ, Fuks Z, Haimovitz-Friedman A, Bartelink H. Role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis. Radiother Oncol. 1998 Jun;47(3):225–32.

  40. 40. 

    Cul J, Zhang M, Zhang YQ, JNK XZH. Pathway: diseases and therapeutic potential. Acta Pharmacol Sin. 2007 May;28(5):601–8.

  41. 41. 

    Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. CpJun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta. 2010 Mar;1804(3):463–75.

  42. 42. 

    Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene. 1998 Dec 24;17(25):3277–85.

  43. 43. 

    Johnson CR, Jiffar T, Fischer UM, Ruvolo PP, Jarvis WD. Requirement for SAPK-Jnk signaling in the induction of apoptosis by ribosomal stress in REH lymphoid leukemia cells. Leukemia. 2003 Nov;17(11):2140–8.

  44. 44. 

    Ventura JJ, Hübner A, Zhang C, Flavell RA, Shokat KM, Davis RJ. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell. 2006 Mar 3;21(5):701–10.

  45. 45. 

    Li J, Xiang S, Zhang Q, Wu J, Tang Q, Zhou J, et al. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting of NF-κB/p65 and MUC1-C. J Exp Clin Cancer Res. 2015 May 15;34:46.

  46. 46. 

    Kuwabara M, Takahashi K, Inanami O. Induction of apoptosis through the activation of SAPK/JNK followed by the expression of death receptor Fas in X-irradiated cells. J Radiat Res. 2003 Sep;44(3):2013–9.

  47. 47. 

    Davies C, Tournier C. Exploring the function of the JNK (c-Jun N-terminal kinase) signaling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem Soc Trans. 2012 Feb;40(1):85–9.

  48. 48. 

    Kim J, Freeman MRJNK. SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat. 2003 Jun;79(3):321–8.

  49. 49. 

    Lee LF, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem. 1998 Oct 23;273(43):28253–60.

  50. 50. 

    Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. Cancer Chemother Pharmacol. 2013;71 Jun,(6):1521–30.

  51. 51. 

    Song Y, Yan H, Chen J, Wang Y, Jiang Y, Tu P. Characterization of in vitro and in vivo metabolites of carnosic acid, a natural antioxidant, by high performance liquid chromatography coupled with tandem mass spectrometry. J Pharm Biomed Anal. 2014;89:183–96.

回到顶部
桌面版